



FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Attorney Docket
23057-XYSerial Number
10/052,498

Applicant

PATIERNO et al.

Filing Date

January 23, 2002

Group Art Unit

1633-1635

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
BL	AA	5,662,896	09/02/97	Barber et al.	424	93	03/17/93
	AB	5,373,095	12/13/94	Johnson et al.	540	95	09/23/93
	AC	5,359,078	10/25/94	Kohn et al.			12/04/92
	AD	5,284,827	02/08/94	Maione et al.	514	12	10/19/90
	AE	5,266,562	11/30/93	Mukherjee et al.	514	15	11/19/97
	AF	5,086,164	02/04/92	Maione et al.	530	324	12/27/89
OV	AG	4,920,016	04/24/90	Allen et al.	424	458	12/18/87
	AH						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Translation
OV	AI	WO 91/07187	5/1991	WO			Yes
	AJ						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AK		Hill, Richard P., Chapter 11, <u>Metastasis</u> , pp. 178-95 in <u>The Basic Science of Oncology</u> , Tannock et al., Eds., McGraw-Hill, N.Y. (1992).
AL		Aznavorian, Sadie et al., "Molecular Aspects of Tumor Cell Invasion and Metastasis," <u>Cancer</u> , 1993, 71(4), 1368-1383.
AM		Singh, Gurmukh et al., "Amino-acid and cDNA nucleotide sequences of human Clara cell 10 kDa protein," <u>BBA</u> , 1988, 950, 329-337.
AN		Nieto, A. et al., "Purification and Quaternary Structure of the Hormonally Induced Protein Uteroglobulin," <u>Arch. Biochem. Biophys.</u> , 1977, 180, 82-92.
AO		Mantile, Giuditta et al., "Human Clara Cell 10-kDa Protein Is the Counterpart of Rabbit Uteroglobulin," <u>J. Biol. Chem.</u> , 1993, 268(27), 20343-20351.

Examiner

D.L.L.

Date Considered

4/27/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.
 Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Attorney Docket
23057-XYSerial Number
10/052,498

Applicant

PATIERNO et al.

Filing Date

January 23, 2002

Group Art Unit

1633 1611

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
						JUL 08 2002

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub Class	Trans-lation
					Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

RM	BA	Miele, Lucio et al., "Uteroglobin: Structure, Molecular Biology, and New Perspectives on Its Function as a Phospholipase A ₂ Inhibitor," <u>Endocrine Reviews</u> , 1987, 8(4), 474-90.
	BB	Miele, Lucio et al., "High Level Bacterial Expression of Uteroglobin, a Dimeric Eukaryotic Protein with Two Interchain Disulfide Bridges, in Its Natural Quaternary Structure," <u>J. Biol. Chem.</u> , 1990, 265(11), 6427-35.
	BC	Sambrook, J. et al., <u>Molecular Cloning: A Laboratory Manual</u> , 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).
	BD	Arcone, Rosaria et al., "Structural characterization of a biologically active human lipocortin 1 expressed in <i>Escherichia coli</i> ," <u>Eur. J. Biochem.</u> , 1993, 211, 347-55.
	BE	Cirino, G. et al., "Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1," <u>British J. Pharmacol.</u> , 1993, 108, 573-574.
	BF	Bastian, Boris Christoph et al., "Inhibition of Human Skin Phospholipase A ₂ by "Lipocortins" Is an Indirect Effect of Substrate/Lipocortin Interaction," <u>J. Invest. Dermatol.</u> , 1993, 101(3), 359-63.
	BG	Ritter, Mary A. et al., Eds., <u>Monoclonal Antibodies - Production, Engineering and Clinical Applications</u> , Cambridge University Press, Cambridge, UK (1995).
	BH	Budavari, Susan et al., Eds., <u>The Merck Index</u> , 11th Ed., Merck & Co., Inc., Rahway, N.J. (1989).
R	BI	Gilman, Alfred Goodman et al., Eds., <u>Goodman and Gilman's: The Pharmacological Bases of Therapeutics</u> , 8th Ed., Pergamon Press, U.S.A. (1990).

Examiner

P. L. L.

Date Considered

7/22/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.
 Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Attorney Docket
23057-XYSerial Number
10/052,498

Applicant

PATIERNO et al.

Filing Date

January 23, 2002

Group Art Unit

1633/675

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
						JUL 08 2002

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
					Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CA	Remington's Pharmaceutical Sciences, 17th Ed., Mack Publishing Co., Easton, PA (1990).
CB	Goldenberg, David M., Ed., <u>Cancer Therapy With Radiolabeled Antibodies</u> , CRC Press, Boca Raton, FL (1995).
CC	Stone, Kenneth R. et al., "Isolation of a Human Prostate Carcinoma Cell Line (DU 145)," <u>Int. J. Cancer</u> , 1978, 21, 274-281.
CD	Horoszewicz, Julius S. et al., "LNCaP Model of Human Prostatic Carcinoma," <u>Cancer Res.</u> , 1983, 43, 1809-18.
CE	Kaighn, M.E. et al., "Establishment and Characterization of a Human Prostatic Carcinoma Cell Line (PC-3)," <u>Invest. Urol.</u> , 1979, 17(1), 16-23.
CF	Hzumi, Tatsuo et al., "Establishment of a New Prostatic Carcinoma Cell Line (TSU-PR1)," <u>J. Urology</u> , 1987, 137, 1304-1306.
CG	Albini, A. et al., "A Rapid in Vitro Assay for Quantitating the Invasive Potential of Tumor Cells," <u>Cancer Research</u> , 1987, 47, 3239-3245.
CH	Leyton, J. et al., "Recombinant Human Uteroglobin Inhibits the in Vitro Invasiveness of Human Metastatic Prostate Tumor Cells and the Release of Arachidonic Acid Stimulated by Fibroblast-conditioned Medium," <u>Cancer Research</u> , 1994, 54, 3696-3699.
CI	Frandsen, T.L. et al., "Assays for the Study of Human Cancer Cell Invasion and Metastasis," <u>Fibrinolysis</u> , 1992, 6 (Supp. 4), 71-76.

Examiner

Dr. J. J.

Date Considered

6/22/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Attorney Docket
23057-XYSerial Number
10/052,498

Applicant

PATIERNO et al.

Filing Date

January 23, 2002

Group Art Unit

1633 (62)

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub- class	Filing Date

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub- Class	Trans- lation
					Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

DA	Manyak, Michael J. et al., "Expression of a Uteroglobin-Like Protein in Human Prostate," <u>J. Urology</u> , 1988, 140, 176-182.
DB	Leyton, J. et al., "Recombinant Human Uteroglobin Inhibits the <i>in Vitro</i> Invasiveness of Human Metastatic Prostate Tumor Cells and the Release of Arachidonic Acid Stimulated by Fibroblast-conditioned Medium," <u>Cancer Research</u> , 1994, 54, 1-4.
DC	Jensen, Sandra M. et al., "Clara Cell 10 kDa Protein mRNA in Normal and Atypical Regions of Human Respiratory Epithelium," <u>Int. J. Cancer</u> , 1994, 58, 629-637.
DD	Linnoila, R. Ilona et al., "Peripheral Airway Cell Marker Expression in Non-Small Cell Lung Carcinoma," <u>A.J.C.P.</u> , 1992, 97(2), 233-243.
DE	Broers, Jos L. V. et al., "Expression of Surfactant Associated Protein-A and Clara Cell 10 Kilodalton mRNA in Neoplastic and non-Neoplastic Human Lung Tissue as Detected by <i>In situ</i> Hybridization," <u>Lab. Invest.</u> , 1992, 66(3), 337-346.
DF	Peri, Alessandro et al., "Tissue-specific Expression of the Gene Coding for Human Clara Cell 10-kD Protein, a Phospholipase A ₂ -inhibitory Protein," <u>J. Clin. Invest.</u> , 1993, 92, 2099-2109.
DG	Miyamoto et al., <u>J. Urology</u> , 149: 1015-1019 (May 1993).
DH	Morgan et al., <u>Annu. Rev. Biochem.</u> , 62: 191-217 (1993).

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE CITATIONAttorney Docket
23057-XYSerial Number
10/052,498

Applicant

PATIERNO et al.

Filing Date

January 23, 2002

Group Art Unit

6638 (1)

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-Class	Filing Date

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub-Class	Translation
					Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

pp	EA	Tolstoshev, Annu. Rev. Pharmacol. Toxicol., 32: 573-96 (1993).
	EB	Leyton et al., Proc. Amer. Assoc. Canc. Res. 35: 280 (1994).
	EC	Mayer et al., Expert Opin. Invest. Drugs, 5: 535-554 (1996).
	ED	Osband et al., Immunology Today, 11: 193-195 (1990).
	EE	Dannhorn et al., J. Immunol. Meth., 119: 223-230 (1989).
	EF	Tibes et al., Expert Opin. Invest. Drugs, 6: 279-298 (1997).
	EG	Aumuller et al., Histochemistry, 83: 413-417 (1985).
	EH	López de Haro et al., FEBS LETTERS, 232: 351-353 (1988).
	EI	Cerbón et al., J. Steroid Biochem., 36: 1-6 (1990).
	EJ	Aihara, T. et al., Can. Lett. 150(79-84), 2000.
R	EK	Anderson et al., Human gene therapy, 1998, Nature, vol. 392, pp. 25-30.

Examiner

Paw 2/2/02

Date Considered

7/27/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.
 Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Attorney Docket
23057-XYSerial Number
10/052,498

Applicant

PATIERNO et al.

Filing Date

January 23, 2002

Group Art Unit

1633 171

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-Class	Filing Date

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub-Class	Translation
					Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

FA	Bodey et al., Failure of cancer vaccines: The significant limitations of this approach to immunotherapy, 2000, Anticancer Research, vol. 20, pp. 2665-2676.
FB	Bowie et al., Science 247:1306-1310, 1990.
FC	Chiu et al., optimizing energy potenetials for success in protein tertiary structure prediction, 1998, Folding & Design, vol. 3, pp. 223-228.
FD	Gomez-Navarro et al., Gene therapy for cancer, 1999, European Journal of Cancer, vol. 35, pp. 867-885.
FE	Liotta, LA Scientific American, pp 54-63, Feb. 1992.
FF	Manyak et al., Uterogloblin inhibition of prostate adenocarcinoma invasion in vitro: A new class of tumor suppressor genes, 1995, The Journal Urology, 153:969.
FG	Ngo et al., The Protein Folding Problem and Tertiary Structure, pp. 492-496, 1994.
FH	Sethna et al., Lung-tumor directed gene therapy using neuroendocrine and lung-tissue specific promoters, 1997, vol. 38, pp. 379.
FI	Shuman et al., Histological presence of viable prostatic glands on routine biopsy following cryosurgical ablation of the prostate, 1997, The Journal of Urology, vol. 157, pp. 552-555.
FJ	Verma et al., Gene therapy-promises, problems and prospects, 1997, Nature, vol. 389, pp. 239-242.

Examiner

B. C. du

Date Considered

4/22/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Attorney Docket
23057-XYSerial Number
10/052,498

Applicant

PATIERNO et al.

Filing Date

January 23, 2002

Group Art Unit

1633 162

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub- Class	Filing Date

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub- Class	Trans- lation
						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

PV	GA		Vile et al., Cancer gene therapy: hard lessons and new courses, 2000, Gene Therapy, vol. 7, pp. 2-8.
I	GB		Watson, MA et al., Can. Res. 59(3028-3031), Jul. 1999.
RN	GC		Wells, Biochemistry 29:8509-8517, 1990.
	GD		
	GE		
	GF		
	GG		
	GH		
	GI		

RECEIVED

JUL 6 8 2002

TECH CENTER 10

Examiner

B. LV

Date Considered

5/22/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.
 Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to Applicant.